title: Transitions to different patterns of interstitial lung disease in scleroderma with and without treatment.
abstract: OBJECTIVE
  The aim is to investigate whether the 12-month quantitative changes in high-resolution CT (HRCT) measures of interstitial lung disease (ILD) are different, and to understand how they change, in patients with scleroderma-related ILD who receive drug therapy versus placebo.
  
  
  METHODS
  HRCT images were acquired at baseline and at 12 months in 83 participants in Scleroderma Lung Study I, a clinical trial comparing treatment with oral cyclophosphamide versus placebo. A computer-aided model was used to quantify the extent of fibrotic reticulation, ground glass and honeycomb patterns and quantitative ILD (QILD: sum of these patterns) in the whole lung and the lung zone (upper, middle or lower) of maximal disease involvement.
  
  
  RESULTS
  Mean QILD score decreased by 3.9% in the cyclophosphamide group while increasing by 4.2% in the placebo group in the most severe zone (p=0.01) and decreased by 3.2% in the cyclophosphamide group while increasing by 2.2% in the placebo group in the whole lung (p=0.03). Transitional probabilities demonstrated greater changes from a fibrotic to either a ground glass or normal pattern in the cyclophosphamide group and the reverse in the placebo group.
  
  
  CONCLUSIONS
  Changes in quantitative HRCT measures of ILD provide a sensitive indication of disease progression and response to treatment.
  
  
  BACKGROUND
  NCT00004563; Post-results.
authors.affiliation: Department of Radiological Science, Center for Computer Vision Imaging Biomarker, David Geffen School of Medicine at UCLA, Los Angeles, California, USA Department of Biostatistics, Fielding School of Public Health at UCLA, Los Angeles, California, USA.
authors.forename: Hyun J
authors.initials: HJ
authors.lastname: Kim
authors.affiliation: Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
authors.forename: Donald P
authors.initials: DP
authors.lastname: Tashkin
authors.affiliation: Department of Radiological Science, Center for Computer Vision Imaging Biomarker, David Geffen School of Medicine at UCLA, Los Angeles, California, USA Department of Biostatistics, Fielding School of Public Health at UCLA, Los Angeles, California, USA.
authors.forename: David W
authors.initials: DW
authors.lastname: Gjertson
authors.affiliation: Department of Radiological Science, Center for Computer Vision Imaging Biomarker, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
authors.forename: Matthew S
authors.initials: MS
authors.lastname: Brown
authors.affiliation: Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
authors.forename: Eric
authors.initials: E
authors.lastname: Kleerup
authors.affiliation: Department of Radiology, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Korea.
authors.forename: Semin
authors.initials: S
authors.lastname: Chong
authors.affiliation: Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
authors.forename: John A
authors.initials: JA
authors.lastname: Belperio
authors.affiliation: Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
authors.forename: Michael D
authors.initials: MD
authors.lastname: Roth
authors.affiliation: Department of Radiological Science, Center for Computer Vision Imaging Biomarker, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
authors.forename: Fereidoun
authors.initials: F
authors.lastname: Abtin
authors.affiliation: Department of Biostatistics, Fielding School of Public Health at UCLA, Los Angeles, California, USA Department of Biomathematics, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
authors.forename: Robert
authors.initials: R
authors.lastname: Elashoff
authors.affiliation: Department of Biomathematics, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
authors.forename: Chi-Hong
authors.initials: CH
authors.lastname: Tseng
authors.affiliation: Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
authors.forename: Dinesh
authors.initials: D
authors.lastname: Khanna
authors.affiliation: Department of Radiological Science, Center for Computer Vision Imaging Biomarker, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
authors.forename: Jonathan G
authors.initials: JG
authors.lastname: Goldin
mesh_terms: D000328:Adult; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000627:therapeutic use*; D018450:Disease Progression; D005260:Female; D006801:Humans; D008168:Lung / Q000473:pathology; D017563:Lung Diseases, Interstitial / Q000209:etiology / Q000473:pathology*; D008297:Male; D012595:Scleroderma, Systemic / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D018501:Antirheumatic Agents; D003520:Cyclophosphamide
keywords: Outcomes research; Pulmonary Fibrosis; Systemic Sclerosis; Treatment